Tatyana M. Kulinich

Tatyana M. Kulinich

Auto-generated profile, based on publicly available information

Tatyana M. Kulinich

Russian Scientific Center of Roentgenoradiology, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2019 in Bulletin of Experimental Biology and Medicine
Verified
Journal Article
Closed access
PDF file
VBVladimir Konstantinovich Bozhenko
Vladimir Konstantinovich Bozhenko
AIA. V. Ivanov
A. V. Ivanov
TKT. M. Kulinich
T. M. Kulinich
VSV. P. Smirnov
V. P. Smirnov
ASA. M. Shishkin
A. M. Shishkin
VSV. A. Solodky
V. A. Solodky

18 January 2024 in Almanac of Clinical Medicine
Verified
Journal Article
Open access
PDF file
VBVladimir Konstantinovich Bozhenko
Vladimir Konstantinovich Bozhenko
SGSergey V. Goncharov
Sergey V. Goncharov
TKTatiana M. Kulinich
Tatiana M. Kulinich
EKElena A. Kukoleva
Elena A. Kukoleva
MFMikhail S. Filippov
Mikhail S. Filippov
VSVladimir A. Solodkiy
Vladimir A. Solodkiy
Background: Ras oncogene mutations leading to hyperactivation of the MAPK/ERK signaling pathway occur in 25% of all human tumors, and for gastrointestinal tumors, the frequency of Ras mutations amounts to 60%. The introduction of a Ras-GTPase inhibitor into clinical practice would increase the effectiveness of the treatment of socially significant diseases such as stomach and intestinal cancer. Aim: To select the optimal dose with a subsequent assessment of the safety of iRAS when administered to patients with gastrointestinal tract tumors, including those with peritoneal carcinomatosis. Materials and methods: This was a prospective open-label non-randomized phase I study for the assessment of safety and tolerability, with an adaptive design and determination of the maximally tolerated dose of the iRAS. Three dose levels were used (0.45 mg/kg, 0.9 mg/kg, 1.8 mg/kg) according to the "3 + 3" scheme. The study included 11 patients after surgery for stomach or colorectal cancer. The patients were administered PIPAC therapy with iRAS twice with a 7-days interval. The study duration was 28 ± 1 days. During the study, the patient monitoring included physical examination, assessment of vital signs, electrocardiography and echocardiography, laboratory parameters (hematology, clinical chemistry, coagulation tests, and urine analysis). Results: The anti-tumor iRAS agent demonstrated satisfactory tolerability of all doses studied, including the maximal 1.8 mg/kg dose. Vital sign and laboratory abnormalities were clinically non-significant and did not require additional therapeutic interventions. Statistically significant abnormalities were registered for total protein (p = 0.00028), white blood cell counts (p = 0.007), lymphocyte counts (p = 0.0008), and a number of other blood parameters; however, most of these abnormalities were within the physiological normal ranges. Vital signs such as electrocardiography and echocardiography parameters remained stable throughout the entire follow-up period (28 days after administration of the drug). There were short-term rises in body temperature, minor pains in the postoperative scar area. Conclusion: This trial of safety and tolerability of iRAS showed that no cases of dose-limiting toxicity in the studied dose range. The 1.8 mg/kg dose can be recommended for further clinical studies.

1 January 2017 in Bulletin of Russian State Medical University
Verified
Journal Article
Closed access
EGE.V. Grabovsky
E.V. Grabovsky
GOG.M. Oleynik
G.M. Oleynik
EKE.G. Krastelev
E.G. Krastelev
VSV.P. Smirnov
V.P. Smirnov
EKE.V. Khmelevsky
E.V. Khmelevsky
TKT.M. Kulinich
T.M. Kulinich

18 October 2019 in Bulletin of Russian State Medical University
Verified
Journal Article
Open access
YKYa.YU. Kiseleva
Ya.YU. Kiseleva
ASA.M. Shishkin
A.M. Shishkin
AIA.V. Ivanov
A.V. Ivanov
TKT.M. Kulinich
T.M. Kulinich
VBVladimir Konstantinovich Bozhenko
Vladimir Konstantinovich Bozhenko
Adoptive immunotherapy that makes use of genetically modified autologous T cells carrying a chimeric antigen receptor (CAR) with desired specificity is a promising approach to the treatment of advanced or relapsed solid tumors. However, there are a number of challenges facing the CAR T-cell therapy, including the ability of the tumor to silence the expression of target antigens in response to the selective pressure exerted by therapy and the dampening of the functional activity of CAR T cells by the immunosuppressive tumor microenvironment. This review discusses the existing gene-engineering approaches to the modification of CAR T-cell design for 1) creating universal “switchable” synthetic receptors capable of attacking a variety of target antigens; 2) enhancing the functional activity of CAR T cells in the immunosuppressive microenvironment of the tumor by silencing the expression of inhibiting receptors or by stimulating production of cytokines.

30 June 2017 in Russian Journal of Biotherapy
Verified
Journal Article
Open access
PDF file
EUE. M. Uchanova
E. M. Uchanova
TKT. M. Kulinich
T. M. Kulinich
EKE. A. Kudiniva
E. A. Kudiniva
VBV. K. Bozenko
V. K. Bozenko
SSS. M. Sitdikova
S. M. Sitdikova
HTH. M. Treshalina
H. M. Treshalina
Терапевтические дозовые характеристики химерного пептида MM-D37K при парентеральном введении мышам Balb/с nude с колоректальным раком человека НСТ-116

15 May 2020 in Advances in molecular oncology
Verified
Journal Article
Open access
PDF file
TKT. M. Kulinich
T. M. Kulinich
MZM. V. Zakharenko
M. V. Zakharenko
EDE. L. Dzhikiya
E. L. Dzhikiya
ASA. L. Senchukova
A. L. Senchukova
USU. S. Stanoevich
U. S. Stanoevich
VBVladimir Konstantinovich Bozhenko
Vladimir Konstantinovich Bozhenko
Background. The search for molecular markers of colon diseases allowing highly specific and sensitive identification and differentiation of pathological processes is a clinically important problem. Expression levels of genes responsible for proliferation can reflect the changes in the affected tissues. The study objective is to perform comparative analysis of molecular and genetic markers of proliferative activity in benign and malignant neoplasms of the colon. Materials and methods. Analysis of the changes in proliferation markers (CCND1, с-MYC, Ki-67, HER2neu, TERT) in adenocarcinoma of the colon (n = 259), resection margin (about 15–20 cm from the tumor lesion) (n = 251), unchanged colon mucosa from healthy donors (n = 247), polyps (n = 28), unchanged colon mucosa intestinal polyposis (10–15 cm from the polyp) (n = 75) was performed using RT-PCR. Results and conclusion. It was shown that morphologically unchanged tissue of intestinal mucosa in malignant tumors has significant differences from normal tissue of healthy donors. Significant differences in the level of expression of genes responsible for the processes of proliferation, с-MYC, CCND1, TERT were found in benign hyperproliferative diseases (polyps). Moreover, these changes were specific to the type of pathological process, which allows us to consider these genes as the most promising candidates in the development of a differential method for diagnosing colon diseases.